7월 27일 · 실적분석
실적분석
Opko Health ($OPK) Q2 2026 Earnings Analysis — Revenue and EPS Beat, Loss Narrows Sharply
OPK Opko Health 실적 요약Opko Health ($OPK) posted Q2 2026 revenue of $163.5 million (vs. $156.8 million a year earlier), well above the consensus of roughly $131.2 million. GAAP loss per share came in at $0.01, a $0.07 improvement versus the consensus loss of $0.08. Net loss collapsed from $148.4 million a year ago to $8.4 million, and the company guided 2026 full-year revenue to $560 million–$585 million. Cash, cash equivalents, marketable securities, and restricted cash totaled $314.4 million. With a market cap of {{MARKET_CAP}} and {{EMPLOYEES}} employees, the company sits at a critical inflection point.
Earnings Scorecard
▸ Revenue: $163.5 million (+4.3% YoY; +24.6% vs. $131.2 million estimate) ✅ Beat
▸ EPS (Diluted): -$0.01 ($0.07 improvement vs. -$0.08 estimate) ✅ Beat
▸ Guidance: Issued — 2026 full-year total revenue of $560M–$585M (Services $296M–$306M, Products $164M–$174M, Intellectual Property and Other $100M–$105M); R&D expense of $125M–$135M
▸ Stock reaction: Trading around $1.35 per share after-hours (roughly +9% vs. $1.24 regular-session close, as of 5:29 p.m. ET) — positive response
The Good
▸ Sharp loss reduction: Net loss narrowed dramatically from $148.4 million to $8.4 million
▸ Revenue beat: $163.5 million, exceeding estimates by roughly 24%
▸ Pharmaceutical segment swings to profit: Operating income of $0.8 million (vs. a $28.7 million loss a year earlier)
The most striking element is the scale of the loss reduction. A year ago, the company posted a $148.4 million net loss ($0.19 per share); this quarter, that figure fell to $8.4 million ($0.01 per share). The operating loss also narrowed from $60 million to $7 million. The fact that a loss-making company has climbed close to breakeven means that for novice investors, the more relevant question at this stage is "how much less did it lose?" rather than "how much did it earn?"
In the pharmaceutical segment, product revenue rose to $42.9 million from $40.7 million a year earlier, and revenue from the kidney-disease treatment Rayaldee increased from $7.2 million to $8.1 million. Profit-share income from the growth-hormone treatment Somapacitan (Engelsa), partnered with Pfizer, also edged up from $6.1 million to $6.4 million. On top of that, intellectual property and other revenue jumped from $15 million to $46.1 million, of which $29.4 million came from a revaluation of the equity stake in Cocrystal Pharma.
The financial position is not bad either. As of June 30, cash, cash equivalents, marketable securities, and restricted cash totaled $314.4 million — equivalent to roughly one-third of its market cap (about $936 million). The company has already executed $105.3 million under the share buyback program approved in July 2025, with $94.7 million remaining, underscoring its capacity for shareholder returns.
The Not-So-Good
▸ Diagnostics segment revenue declines: Revenue fell 26%, from $101.1 million to $74.5 million
▸ One-time item dependency: Of the surge in intellectual property revenue, $29.4 million came from an equity-stake revaluation
▸ Annual costs exceed revenue: Guided total costs of $710M–$740M vs. revenue of $560M–$585M
Diagnostics (services) revenue fell from $101.1 million a year earlier to $74.5 million. The company explains that the prior-year figure included $24.9 million from the now-divested oncology diagnostics assets. Stripping that out, the decline looks far smaller, but the underlying business is still smaller in scale, and it remains unproven whether the remaining diagnostics franchise can rekindle growth.
It's also worth flagging that of the $46.1 million in intellectual property and other revenue that lifted this quarter's top line, $29.4 million came from the revaluation of the Cocrystal Pharma stake. Items like this are accounting-style valuation gains rather than actual cash inflow, so there is no guarantee they will recur next quarter. Excluding this component, a meaningful share of the revenue beat disappears.
Most importantly, looking at the 2026 full-year guidance the company itself provided, total cost and expense projections ($710M–$740M) exceed total revenue projections ($560M–$585M) by more than $130 million. In other words, the company itself is guiding to an operating loss for the full year. The near-breakeven result this quarter is an encouraging signal, but a full-year return to profit is still some distance away.
What Management Said
Alongside the financial numbers, the company placed meaningful emphasis on progress in its drug pipeline during the earnings release. Modex, its subsidiary, has initiated a Phase 1 clinical trial of MDX2003, a candidate for the treatment of B-cell lymphomas, and also announced that MDX2301, a COVID-19 prevention antibody funded by the U.S. Department of Health and Human Services' BARDA, has entered Phase 1 trials. The company noted that patient enrollment continues for solid-tumor therapeutics and its immune reactivation programs.
On guidance, the message management delivered was closer to "we'll defend revenue, but we won't cut R&D investment." The $125M–$135M annual R&D budget is the supporting evidence. The fact that management is talking about loss reduction and pipeline investment at the same time suggests the market may place more weight on when Modex's clinical data emerges than on this quarter's headline numbers.
Market Reaction and What to Watch Next
The core of this report is not "growth" but "loss control." Revenue did beat estimates by more than 24%, but a sizable portion came from a one-time equity-stake revaluation, while underlying business revenue rose only about 4% versus a year ago. On the other hand, the reduction in net loss from $148.4 million to $8.4 million signals that the cost structure has genuinely improved — meaningful for investors sizing up the viability of a loss-making company.
Because the release came after the U.S. market close, the $1.24 regular-session close does not reflect the results. In after-hours trading, the shares are changing hands around $1.35 (roughly +9% versus the close), a positive reception. That said, with the share price in the low-$1 range, even a small absolute move can translate into a large percentage change — a point worth keeping in mind. The $314.4 million in cash, cash equivalents, marketable securities, and restricted cash, equal to one-third of market cap, also provides some downside support.
▸ Whether revenue still grows even after excluding one-time items such as equity-stake revaluations
▸ Whether diagnostics revenue finds a floor at the $74.5 million level and rebounds
▸ Whether the path to the full-year guidance ($560M–$585M total revenue) is confirmed by second-half results
▸ Whether Modex delivers any initial data or progress updates from the Phase 1 trials of MDX2003 and MDX2301
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.
🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다